Rocket Pharmaceuticals has voluntarily withdrawn its biologics license application to the FDA for RP-L102, a gene therapy candidate targeting Fanconi anemia, a rare blood disorder. This decision follows a strategic company restructuring that redirected focus toward cardiovascular programs. The withdrawal stems from business considerations and pipeline reprioritization rather than safety or efficacy concerns. Rocket intends to explore external partnership opportunities to advance the therapy in the future. This marks a pause in their rare hematology asset development after prior regulatory challenges and clinical holds on other programs.